Director, Global Commercial Leader, Early Heme Pipeline

BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer.

General Description:

BeOne, a global oncology company, has produced a robust pipeline of New Molecular Entities (NMEs) with potential to change the standard of care across numerous disease areas. More than 10 additional NMEs can be expected from the Discovery organization in 2026, adding to an already comprehensive set of molecules spanning multiple modalities and which are currently in early- and late-stage Clinical Development.  This pipeline maturation has driven One growth and generated challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly share our passion to fight cancer and our commitment to serve patients wherever they reside.

As the Director/Associate Director, Global Commercial Leader, Early Hematology Pipeline, you will play a critical leadership role in our newly formed Global Commercial Strategy and Operations team. You will be responsible for overlaying a commercial perspective that guides our Research and Development efforts in the Hematology therapeutic area, with efforts to help create differentiated Target Product Profiles (TEPs/TPPs), sizing commercial opportunities, generating insights into patient and physician unmet needs, and guiding investment into the most productive and impactful areas. You will serve as the Commercial voice on the Early Development Teams (EDTs) helping to ensure a robust evidence package that meets the needs of various Regional stakeholders including Regulatory and Reimbursement bodies around the globe. You will also play a leading role in helping to develop our pan-Hematology strategy.

This role requires comprehensive knowledge of the Hematology therapeutic area landscape, a deep understanding of the drug development process, and a keen business acumen. This role will serve as the primary Commercial lead into R&D/ Clin Dev governance decisions. The ideal candidate brings deep Hematology market knowledge, strong scientific fluency, and a track record building early commercial business cases that guide R&D, BD, and investment decisions.  The role reports to the Vice President, Global Commercial Hematology Franchise Lead.

Essential Functions of the job:

• Create and ensure execution of the insights generation plan that helps inform BeOne understanding of unmet needs, likely evolution in the standard of care, and key stakeholder requirements to drive adoption of emerging therapies. 
• In partnership with the Business Insights (CBDI) team, ensure a comprehensive understanding of the relevant patient segments, marketplace events, competitive landscape, and industry pipeline across the Hematology therapeutic area.  Present key updates as needed to Project and Executive teams.
• In close coordination with Early Development Teams, ensure a comprehensive set of TEPs/TPPs are developed and maintained.  As a best practice, the TEPs/TPPs will be based upon deep customer and competitive insights which guide the development of differentiated assets. 
• Partner with the Pipeline and BD valuation team to quantify the commercial potential of target patient populations as identified within the TEPs/TPPs and ensure full evidence requirements to secure global reimbursement are captured within the TEP/TPP and asset development plans.
• Represent ONE commercial voice to Early Development Teams (EDTs), including the priority early Heme programs. Coordinate with other commercial stakeholders to ensure an integrated, global commercial perspective is included in early asset development decisions.
• Partner with relevant functions to maintain pipeline valuation metrics for the early Hematology portfolio, ensuring any investment decisions are supported by robust commercial assessments and balance BeiGene priorities on risk / return considerations, and speed to the marketplace.
• Collaborate with cross-regional and cross-functional team members to shape disease area strategies for multiple indications, including our overall BeOne pan-Hematology strategy.
• As required, guide commercial decisions regarding early asset positioning, messaging, and branding considerations prior to the formation of Global Product Teams (GPTs).
• In close coordination with cross-functional team members such as Medical Affairs and Corporate Affairs, identify partnership opportunities with Hematology patient organizations and define/execute tactics aligned to the shared agenda of disease education and improvin